Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Article on CNN about an apparent Alzheimer's reversal, subject is double APOE4. https://www.cnn.com/2024/05/18/health/alzheimers-blood-brain-improvement-wellness/index.html
Missling will be participating Monday in a "fireside chat" on Monday at the HCW BioConnect, an investor conference. Unlikely to hear anything new in this, but keep eyes out for announcement of presentation at an AD medical conference, which could be an opportunity to present extended findings from our 2b/3. If journal publication proves untimely, he recently sounded inclined to pre-empt it.
George
People that only speak about the positives while ignoring the negatives aren't pumpers?
I own more shares than ever, but I enjoy looking at both sides..from my perch, it is easy to see those here that have an agenda, either positive or negative...
I'm not making this up, years ago, someone was so over the top, they said the following after a failed phase II:
"This is good news, now we won't have to pay for an expensive phase III trial, extending our cash runway "..
I'm just curious...Are you ever going to admit that Missling did a good job at financing the studies? After all, you complained for years that he was doing it in the wrong way. So much so that if you ever said anything positive, it wasn't apparent!
You do know that the company you keep in the emoji circus
already has a ringmaster and a driver for that clown car.
What is your function?
Even LTB can not compete with your rightful place at the top of the list.
The drop from 10-4 has made it untenable for him to portray
a prescient sell to avoid a $6M loss no matter how fictitious..
Look in the mirror.
“(2) We appreciate this new guidance and believe this opens another possible pathway for us to move forward in parallel to the initiated process of market authorization application to the European Medicine Agency, EMA, for blarcamesine for the treatment of Alzheimer’s disease which is already underway.”
Welcome back Abew! I know we have said it before but “next year this time” we should be in for a real treat. I entered into this stock in 2015 and after a decade of trials, 2025 WILL be the year for Alzheimer’s approval.
Looks like from the above statement that the Fda submission of an NDA (at least preparing large portions) will be happening in parallel.
The shorts were successful in scaring and driving out retail many times along the way, Im just glad you were able to reenter at a lower price.
Cheers
Tred
Thanks for sharing Dr Cox's research. Interestingly, some pre-clinical clinical research shows that L-serine can induce neurodegeneration, while other research shows it can reduce it. The clinical trial underway will help determine which, and hopefully it's the latter. This amino is used in various parts of the body, so over-supplementing it might have side effects. More research is being done.
AD is complex. An effective therapy will likely ultimately have several drug components, treating different aspects of the overall pathology. This amino, or others, could be one, as could an S1 agonist like ours.
Chris--" she seems to be well liked by all."--great find--thanks for posting ! More progress being made by company !!!!!
It looks like she was brought into the company by Terrie Kellmeyer who joined the company just 7 months ago as Sr. VP of Clinical Development and who she worked with at Acer. Great people hang with great people. Anavex continues to make some great hires.
Ok this to me is a great addition to the team.
http://linkedin.com/in/kim-tharaldsen
She looks to be filling a huge patient advocacy type need and by the looks of the people wishing her success she seems to be well liked by all.
Which explains why in most cases when I cut and paste I provide a link to the source so each reader that cares can make their own evaluation of the source.
Yes AVXL 20% up this week!
Nice post. I'm wondering if perhaps the "peer reviewed" thing was always waiting upon this perhaps expected change in the FDA's requirements for approval.
Wouldn't that make a lot of sense? What if our trial results had been published before this change? Wouldn't our kind of iffy results be met then with a yawn and soon forgotten? But if they are published now - after the more lenient FDA approach - they will be dramatic. And they will be noticed.
After the publication, all the other upcoming Anavex doings that Missling listed there will also take on a new significance ... and get noticed. The street - in Missling's new favorite word - will be "intrigued"!
"(1) We’re encouraged by the very recently issued FDA guidance for early Alzheimer’s disease which states that one cognitive measure alone like ADAS-Cog could be a sufficient primary endpoint for early Alzheimer’s disease...."
Of course not.
As a casual observer of any political campaign ad will see, it is more effective to scare people into action than it is to entice them. Shorts and those wanting to buy at a lower price employ scare tactics to influence shareholder behavior.
Attempting to manipulate buying is more difficult. Sure you can paint a rosy picture of the future, after all that is what most ads on TV do, but most investors have already done their research and have a pretty good idea what they bought and why they did. Enticing them to buy more runs up against some real resistance in terms of dry powder, portfolio allocation limits, and other competing investment opportunities.
I suggest that the total effect on the share price of "pumping" is minimal and thinking that a single poster or even several have any effect on the share price is quite a reach.
Compare the relentless drum beat of the multiple negative posters vs the few hard core positive posters and the numbers of posts are heavily skewed toward the negative. But then it is much easier to make money on the short side in the absence of significant progress. Once that significant progress happens, being on the short side will be a bit more challenging. Of course 20,000,000 share short position with a value of $100,000,000 or more has no real competition on the long side so far, although the tutes seem to be increasing their positions. Remember that the vast majority of the shares held by the tutes are in index funds and are not actively protected as are the short positions.
We await significant progress to see how this will play out.
I have my tickets to the show and will have popcorn at the ready when the show starts.
Certainly depends on WHO/WHAT
you believe to be credible source(s).
Factor mis interpretation and you have the
majority on contributions here.
As to why I bother....I am about as transparent a trader in AVXL as there
may be in this environment. And I don’t use a Ouija board or TARDIS.
There are absolutely no pumpers on this AVXL discussion board. You can't name even one pumper on this AVXL board.
Good luck and GOD bless,
APOE in Super-Seniors
So you believe that PUMPers really get people to buy??
It's like buying a house you've never seen
Marrying someone you haven't met
Sticking your finger (or some other appendage) in a hole where you don't know what's on the other side
Every day this week was a green gain of the previous day. A solid green week, it has been quite a while since AVXL pulled that hat trick.
Pure as the driven snow! Compares to Ivory Soap...99 44/100 percent pure! You've been negative for over ten years...
That would depend on what information the directors have compared to management. It is entirely possible for management to have information that the directors are unaware of.
Still that does look like splitting hairs.
Which begs the question, why are you here? 😉
I find it very useful in the contentious environment of this board. I call it quoting the source as opposed to expressing information second hand.
Joseph, Thanks for taking the time to find that and post it.
Here’s the difference: I’m not deceitful and I don’t have ulterior motives, such as urging people to sell so that I can quietly buy on the cheap. I am not a short seller. I have strong opinions on Anavex’s leadership based on my professional experience and observations that some may disagree with but at least I’m being honest. I’m also always prepared to hear other viewpoints and am ready to be wrong. Otherwise, I’d have no reason to post here. And by the way, if you’ve read my posts you know that on more than one occasion I’ve credited Missling with getting Anavex onto Nasdaq, putting cash in the bank, and getting trials going. However, I do believe he’s now in over his head. He should get the proverbial gold watch and move on so that new, more qualified leadership can take the company over the goal line or at least give it a fair chance to do so.
The PUMPers here (one in particular) do have an ulterior motive, which is to sucker people into buying so that they can sell into a rising market while offering God’s blessings in the process of turning well-meaning investors into bag holders. This comes from Chapter 1 of the PUMPers handbook. It’s vile and shameful but I guess it works or else why bother.
DO NOT FORGET!!!
"...Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ being held May 20th, 2024 at 10:00am ET at NASDAQ World Headquarters New York City.
A live audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. An archived edition of the session will be available later that day...."
https://www.anavex.com/post/anavex-life-sciences-to-present-at-the-h-c-wainwright-2nd-bioconnect-investor-conference-at-nasdaq
Good luck and GOD bless,
I wouldn’t exactly call your posting history overly “balanced” either. You assume the most negative interpretation of every development and predict the worst possible outcome on almost every issue discussed. Then, inconsistently, you describe your pervasive negative viewpoints as merely not liking the CEO.
Background of Thomas Steffen and this pending lawsuit
...suggests, at least to me. that his 15 years of experience in litigation and patent law & intellectual property having worked with Takeda and a German Patent Law Firm convinced him of this worthwhile add on to his holdings in Anavex Life Sciences...I assume he is positive on the eventual legal outcome of all pending efforts with their lead guy..
With a long history of stating total bs as fact, maybe he should apply for a job at some news media channel. He would fit right in. Or maybe some religion channel. A lot of them seem to have their own game going on.
Speaking for myself, I have no problem with people posting positive sentiments, even if I disagree. What bothers me is the lack of balance or context. For example, posting 6 year old videos of Ern Heaven without pointing out that 1) the video is old, 2) that it is possible for temporary improvements in AD patients, and 3) that we have no idea whether Ern is alive or dead. Or how about when George talks how great some patient with schizophrenia is going to do after taking 3-71 without pointing out that a trial hasn’t even been completed yet, so we actually don’t yet know whether any patients will do well or not.
It’s one thing to express optimism. It’s another thing to attempt to deceive or draw in the unsuspecting dumb retail, I.e. pumping for hidden reasons.
That’s very funny coming from the most notorious PUMPster ever to infect a stock message board.
Missling never said anything about an EMA filing in the first half. He said as soon in 2024 as is possible. Which timeline also must take into account the EMA rule about the soonest date they can file.
What is so powerful about those catalyst? They are not new, if you check last 10 earning PRs, you will find same bullet points except FDA. EMA filing was suppose to finish mid 2024, now end 2024, kick the can is in full swing. He has no control on his progress, he just makes up stuff as he goes.
I bought back in this morning with a sizable position. It's not as big as before, but it's good enough to make a small fortune if AVXL hits a home run...and I firmly believe they will.
After reading the transcript of the 2Q conference call, I want to highlight that we had three analysts on the cc as opposed to having none on the previous two conference calls. Why is this important?
Because I believe TGD specifically contacted those analysts to let them know that things have taken a dramatic turn for the company...and they need to be aware of what's about to happen. I'm sure that you've already read the full cc so I won't reprint everything here...but I do think it's important that you re-read TGD's opening comments:
Thank you, Clint, and good morning, everyone. Thank you for being with us today to review our most recently reported financial results and to provide our quarterly business update.
(1) We’re encouraged by the very recently issued FDA guidance for early Alzheimer’s disease which states that one cognitive measure alone like ADAS-Cog could be a sufficient primary endpoint for early Alzheimer’s disease.
(2) We appreciate this new guidance and believe this opens another possible pathway for us to move forward in parallel to the initiated process of market authorization application to the European Medicine Agency, EMA, for blarcamesine for the treatment of Alzheimer’s disease which is already underway.
(3) Full data from the blarcamesine study in Alzheimer’s disease Phase 2b/3 placebo-controlled clinical trial will be published in an upcoming peer-reviewed journal, (4) as well analysis of RNA sequencing of the trial is underway and interim data is expected by mid-2024.
(5) Concurrently, the ATTENTION-AD open-label extension trial is ongoing and we expect to be able to share interim data in the second half of 2024.
(6) In Rett syndrome, continued positive real-world evidence feedback from Rett syndrome patients and caregivers participating in the ongoing open-label extension trial and Compassionate Use Program for patients who participated in the EXCELLENCE trial encourages us to continue our partnership with the Rett syndrome community and to proceed with a Phase 3 12-week efficacy study. An educational presentation will be provided at the 2024 IRSF Rett Syndrome Scientific Meeting, taking place this year June 18, 2024 to June 19, 2024.
(7) Regarding Parkinson’s disease, initiation of an ANAVEX2-73 Phase 2b/3 six-month trial is expected in the second half of 2024.
(8) In Fragile X, new specific translatable and objective biomarker data generated with ANAVEX2-73 supporting the initiation of the potentially pivotal ANAVEX2-73 Phase 2/3 clinical trial will be presented at the 19th National Fragile X Foundation Conference taking place in July 25, 2024 to July 28, 2024.
(9) Related to a new rare disease, we are also in preparation to initiate a potentially pivotal ANAVEX2-73 Phase 2/3 trial.
(10) With respect to ANAVEX3-71, we are quite pleased to provide an update that the placebo-controlled Phase 2 clinical trial of ANAVEX3-71 for the treatment of schizophrenia. The study is well underway with the first cohort of schizophrenia patients being fully enrolled. We are also expecting further peer-reviewed clinical publications in both -- involving both ANAVEX2-73 and ANAVEX3-71.
These are very powerful points and I numbered each one so that you could clearly see why TGD wanted these analysts to participate in this conference call. The bottom line is that Anavex may finally be transitioning from a baby biotech into a pharmaceutical company by the end of next year.
Additionally, assuming we submitted the request for Accelerated Assessment with the EMA, we should get an answer within the next 30 - 60 days...so be prepared for a possible pop in our share price by mid-June or mid-July.
Cheers.
abe
VERY NICE K9UWA.I AM HAPPY FOR THEM.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
july next year i'll be here 10 years if i am not above my average i will dump all my shares and moving on because i believe bio needed 7 to 10 completing the trial process.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
buddy's add under $4 A big DITTO 3.50 to 4.00 I doubled my share holding. Funny I too have MS & MCD. In my case it is for great grandkids College funds
John k9uwa
Kund:
His mistake was when he exercised about 1/2 of the 500K options thinking that RETT would be a payoff as you had mentioned at that time, so I don't think he made a mistake in doing the cashless exercise of those 73K shs this time to offset this problem and lack of impressive "Excellence Trial"....he has another 500K coming up in 2025...so that's pretty good @ an exercise price of $.92 cents....
Maybe he catches this one and smiles as some here do also!
KUND my average 1.8M shares $5.17 what do you think ?.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
also KUND a lot of my buddy's add under $4 as well do you think they going making the killing??.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
WilliamMunny
True statement based on that!
At least we do know that now "the window is open"....hope a few insiders will decide to do a direct open market purchase...for me, I do see the break of the 50day as good which points at least towards $5.50 to $6.20 near term as next resistance...I'm hopeful, but certainly not cocky...been happy with MCD (super) and HD (not so much recently)...still love COST and MS...that's 4 with 4 more with this "spec" holding for my grandkids...hope I live to see them smile with this one
KUND i add 250k shares range from $3.3 to $3.75 do you think i am going to making killing ??.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
They made killing from $12 to $3.50, along with them Misleading made his great loot.
When is Misleading going to buy his 350 shares? or he knows only selling free options. All those WGT talks of "partnership" are gone, insider won't buy if there was one. There is nothing going on inside this company, next fireside chat Misleading going to say billions of pages for EMA submission. There need to be fire under Misleading's arse, hope BOD just replace him with someone who can at least tell the truth about data and (no)progress.
Followers
|
1065
|
Posters
|
|
Posts (Today)
|
17
|
Posts (Total)
|
459328
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |